The FDA is working to pull illegal products from the marketplace to protect public health, seeking to stop US sales of numerous products illegally marketed as diabetes treatments.
After deliberating, an FDA advisory panel voted to recommend the comprehensive and severe restrictions on Avandia (rosiglitazone) be changed.
A new study published in the Journal of the American Medical Association suggests that low levels of melatonin could increase the risk of developing type 2 diabetes.
According to a new report from the American Diabetes Association, diabetes cost Americans $245 billion in 2012, a 41 percent increase since 2007.
LifeScan, Inc. has issued a voluntary recall of its OneTouch Verio IQ glucose meters in the United States. Learn why they are recalling the meters and how to receive a replacement meter.
Insulinindependence, an organization that merged with the Diabetes Exercise and Sports Association in 2012, announced it will host the 2013 North American Conference on Diabetes and Exercise on August 16-18 in San Diego, California.
Epinex Diagnostics, Inc., a company developing a point-of-service test for glycated albumin, disclosed to the SEC it had raised funds from private investors and could raise up to $1.7 million in a private equity offering.
A new study published in the journal JAMA Internal Medicine found that patients taking GLP-1 therapy drugs, such as Januvia and Byetta, were at twice the risk of developing pancreatitis.
A new study revealed the heart drug Ranexa may reduce chest pain in individuals with type 2 diabetes, and may even have glucose-lowering potential. Learn more.
The FDA rejected applications from Novo Nordisk to market its two new insulin products, Tresiba and Ryzodeg. The FDA wants the pharma company to complete a new cardiovascular study about the safety of the drugs.
A 2012 study published in the journal Neurology found a relationship between high, but normal blood sugar levels, and loss of brain function. This type of function is commonly found in dementia-related diseases, such as Alzheimer's.
Japan's health regulator has approved Novo Nordisk's latest combination drug to treat diabetes. Ryzodeg combines long-acting insulin, Tresiba, with its rapid-acting insulin, NovoRapid.
Women with a history of breast cancer are at higher risk of developing diabetes, according to a new study published in the journal Diabetologia.
Omada Health recently launched Prevent, an online, 16-week program designed to help participants lose weight and avoid diabetes. Learn more about Omada Health and the Prevent program.
Poxel SA announced it has raised $17 million of Series B funding to advance development and testing of an experimental new class of oral anti-diabetic drugs called Glimins.
Ford is working with medical professionals and other companies to research and develop a series of health apps that would work while in a car. These apps are aimed at helping consumers manage their health in real-time, even when behind the wheel of their car.
receive the latest information about glucose
meters, diabetic supplies, and product offers
right to your inbox. Get started today.